Literature DB >> 3935948

Suppression of the development of experimental allergic encephalomyelitis by suramin.

R C van der Veen, S S Asghar, B M Uitdehaag, H J van der Helm, O R Hommes.   

Abstract

Suramin was tested for its ability to suppress experimental allergic encephalomyelitis. Prophylactic administration caused significant reduction in the severity of the disease, incidence of paralysis and cellular infiltration in nervous tissue. Therapeutic treatment with suramin also caused a reduction in the severity of the disease, the incidence of paralysis and cellular infiltration, but to a lesser extent. Significantly fewer animals were paralysed for more than two days on therapeutic treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935948     DOI: 10.1016/0028-3908(85)90206-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  3 in total

1.  P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase.

Authors:  W Panenka; H Jijon; L M Herx; J N Armstrong; D Feighan; T Wei; V W Yong; R M Ransohoff; B A MacVicar
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

2.  Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production.

Authors:  M Shenoy; B MacPherson; P Christadoss
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

3.  Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat.

Authors:  S Jung; K V Toyka; H P Hartung
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.